Seeking Novel CNS Indications and Mechanistic Pathways for RIPK1 Inhibition

A global pharmaceutical company has developed a CNS-penetrant receptor-interacting protein kinase 1 (RIPK1) inhibitor and is actively seeking partners with expertise in RIPK1’s role in human pathophysiology to identify promising disease indications that will guide further development of the inhibitor.

Approaches of Interest:

• Identification of promising CNS disease indications that are driven by the RIPK1 pathway for inhibitor development:
  • Both genetic rare diseases and common diseases are acceptable
  • For common diseases, information that supports patient...